This study demonstrates that CLTB promotes HCC progression through the NF‐κB–PCLAF signaling axis and sEV‐mediated vascular remodeling, providing a mechanistic foundation for developing combination therapies targeting CLTB. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.